Hikma Pharmaceuticals PLC (LSE:HIK) Annual Report 2021



The latest annual report of Hikma Pharmaceuticals PLC (HIK) was published on 31 Dec 2021. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - HIK Annual Results

Amounts in USD

Total Revenue
2.55B
Gross Profit
1.3B
EBIT
561M
Net Tangible Assets
1.56B
Net Income
421M
Capital Expenditures
-145M

HIK Income Statement 2021 Annual Report

As per the latest Income Statement of HIK, the Net revenue increased by $212.00M (9%) compared to the previous period. The operating income in 2021 increased by $21.00M (4%). The net income as per the annual report was 421M which decreased by $-10.00M (-2%) compared to previous year.

Income Statement Report (2021/2020)

20212020
Total Revenue2.55B2.34B
Gross Profit1.3B1.21B
Operating Income561M540M
Income Before Tax544M558M
Net Income421M431M

Balance Sheet - HIK 2021 Annual Report

Read further: HIK Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Hikma Pharmaceuticals PLC showed the company increased the cash on balance sheet by $103.00M (32%). The Net tangible assets of HIK on the balance sheet were at 1.56B which is $302.00M (24%) more than previous annual report. The total stockholder equity also increased by $318.00M (15%) compared to previous reporting period.

Balance Sheet Statement Report (2021/2020)

20212020
Cash426M323M
Total Assets4.37B 4.13B
Long Term Debt651M692M
Total Liabilities1.91B 1.99B
Total Shareholder Equity2.45B2.13B
Net Tangible Assets1.56B1.26B

Cash Flow Statement - HIK 2021 Annual Report

The 2021 annual cash flow statement of Hikma Pharmaceuticals PLC showed that the net income decreased by $-10.00M (-2%) compared to previous reporting period. Also the capital expenditure of HIK increased by $27.00M (16%).

As of 2021, the total cash from investing activities was -238M and total cash from financing activities was -287M.

Cash Flow Statement Report (2021/2020)

20212020
Net Income421M431M
Capital Expenditures-145M-172M
Dividends Paid-120M-109M
Total Cash From From Investing Activities-238M-283M
Total Cash From From Financing Activities-287M-298M

Hikma Pharmaceuticals PLC Annual Report History

Income Statement

Income Statement history of Hikma Pharmaceuticals PLC (LSE:HIK)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Total Revenue2.55B2.34B2.21B2.07B
Cost Of Revenue1.25B1.13B1.11B1.07B
Gross Profit1.3B1.21B1.1B1B
Research Development143M137M126M118M
Selling General Administrative561M506M487M467M
Non Recurring----
Other Operating Expenses36M30M30M-9M
Total Operating Expenses1.99B1.8B1.72B1.64B
Operating Income561M540M486M428M
Total Other Income Expense Net-17M18M5M-135M
Ebit561M540M486M428M
Interest Expense-43M-41M-36M-41M
Income Before Tax544M558M491M293M
Income Tax Expense124M128M4M8M
Minority Interest14M13M12M12M
Net Income From Continuing Ops420M430M487M285M
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Charges----
Other Items----
Net Income421M431M486M282M
Net Income Applicable To Common Shares421M431M486M282M

Balance Sheet Statement

Balance Sheet Statement history of Hikma Pharmaceuticals PLC (LSE:HIK)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Cash426M323M442M276M
Net Receivables876M736M747M745M
Inventory695M757M568M528M
Other Current Assets8M26M19M41M
Total Current Assets2.09B1.92B1.85B1.67B
Long Term Investments46M34M29M38M
Property Plant Equipment1.15B1.07B962M870M
Good Will285M289M282M279M
Intangible Assets607M587M552M487M
Other Assets194M235M257M155M
Deferred Long Term Asset Charges183M221M243M125M
Total Assets4.37B4.13B3.93B3.5B
Accounts Payable262M279M286M263M
Short Long Term Debt48M41M509M9M
Other Current Liab328M304M350M275M
Long Term Debt651M692M48M539M
Other Liab164M195M223M345M
Minority Interest14M13M12M12M
Total Current Liabilities1.02B1.03B1.47B893M
Total Liab1.91B1.99B1.8B1.8B
Common Stock42M41M41M40M
Retained Earnings2.19B1.89B1.97B1.58B
Treasury Stock-60M-80M-179M-217M
Capital Surplus282M282M282M282M
Other Stockholder Equity-60M-80M-178M-216M
Total Stockholder Equity2.45B2.13B2.12B1.69B
Net Tangible Assets1.56B1.26B1.28B919M

Cash Flow Statement

Cash Flow Statement history of Hikma Pharmaceuticals PLC (LSE:HIK)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Net Income421M431M486M282M
Depreciation169M125M107M99M
Change To Netincome67M106M-87M64M
Change To Account Receivables-166M-47M21M-41M
Change To Liabilities14M6M-6M88M
Change To Inventory38M-180M-25M-51M
Change To Operating Activities84M13M-34M-21M
Total Cash From Operating Activities638M464M472M430M
Capital Expenditures-145M-172M-119M-107M
Investments3M-3M8M-4M
Other Cashflows From Investing Activities-12M-56M33M48M
Total Cashflows From Investing Activities-238M-283M-151M-96M
Dividends Paid-120M-109M-97M-84M
Net Borrowings-114M220M-10M-141M
Other Cashflows From Financing Activities-53M-34M-48M-53M
Total Cash From Financing Activities-287M-298M-155M-278M
Effect Of Exchange Rate-10M-2M-2M-7M
Change In Cash103M-119M166M49M